Company intelligence / Profile preview

ForSight Vision2

Ownership: Private
Development stage: Other

Overview

ForSight Newco II (also known as ForSight Vision2) developed a proprietary ocular punctal plug drug delivery system, a non-invasive implantable device designed to deliver pharmaceutical agents directly to the eye. The platform technology, which reached Phase 3, specifically targeted glaucoma treatment to improve patient compliance by replacing daily topical eye drops. This technology had the potential for multiple product opportunities beyond glaucoma.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

QLT Inc.

Beyond the preview

Go deeper on ForSight Vision2.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ForSight Vision2.

Explore the full profile